They are acompany focused on the development of products for the treatment of urological disorders. Recently had a positive outcome for the Phase II clinical
study of PSD502 for the treatment of premature ejaculation.
Current product pipeline
* PSD502 (treatment for premature ejaculation)
- nearing completion of Phase II clinical trials, trials initiated on
secondary use for the treatment of pain in burns and wounds
* PSD503 (treatment of stress urinary incontinence - SUI)
- expect to commence Phase II trials Q4 2005
* PSD506 (treatment of overactive bladder in both male and female
patients)
- signed license agreement with Hoffman-La Roche giving Plethora
exclusive access to PSD506 for Phase II development in 2006
* PSD401 (novel device for use in diagnosis of premature ejaculation)
- successful completion of clinical development programme
- collaborative agreement with Johnson & Johnson for use of PSD401 in
clinical trials for treatment for sexual dysfunction
New Product
* PSD597 - new programme initiated for the treatment of interstitial
cystitis
Price target raised to 526p.
Thursday, December 01, 2005
Collins Stewart upgrades Plethora Solutions (PLE.LN) target price to 526p from 338p. Says the phase IIb results for PSD502 validate the drug as having clear potential to be not only the first product to the market to treat premature ejaculation, but also the leading product in a market which will be substantially larger than the erectile dysfunction market today. Shares +19% at 145p.
